Testing effectiveness (Phase 2)UnknownNCT00003327What this trial is testingPaclitaxel in Treating Patients With Recurrent or Refractory Head and Neck CancerWho this might be right forHead and Neck Cancer Theradex 60
Early research (Phase 1)Study completedNCT01017185What this trial is testingStudy of HF10 in Patients With Refractory Head and Neck Cancer or Solid Tumors With Cutaneous and/or Superficial LesionsWho this might be right forRefractory Head and Neck CancerSquamous Cell Carcinoma, SkinCarcinoma of the Breast+1 more Takara Bio Inc. 28
Not applicableUnknownNCT06068127What this trial is testingG-POEM for Refractory Gastroparesis After Esophagectomy With Gastric Pull-throughWho this might be right forGastroparesisEsophageal Cancer Institute for Clinical and Experimental Medicine 30
Early research (Phase 1)Study completedNCT03739931What this trial is testingDose Escalation Study of mRNA-2752 for Intratumoral Injection to Participants in Advanced MalignanciesWho this might be right forDose Escalation: Relapsed/Refractory Solid Tumor Malignancies or LymphomaDose Expansion: Triple Negative Breast Cancer, HNSCC, Non-Hodgkins, Urothelial Cancer, Immune Checkpoint Refractory Melanoma, and NSCLC Lymphoma ModernaTX, Inc. 134
Not applicableStudy completedNCT03377270What this trial is testingClinical Impact of Respiratory-Swallow Training on Refractory Dysphagia in Oropharyngeal Head and Neck CancerWho this might be right forHead and Neck CancerDysphagia VA Office of Research and Development 49
Very early researchLooking for participantsNCT06898437What this trial is testingStudy of 177Lu-LNC1004 Injection in FAP-positive Radioiodine-refractory Differentiated Thyroid CancerWho this might be right forRadioiodine Refractory Differentiated Thyroid Cancer Peking Union Medical College Hospital 20
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07529873What this trial is testingPhase II Study of Ficerafusp Alfa in Combination With Nivolumab in Patients With Platinum-refractory Head and Neck Squamous Cell CarcinomaWho this might be right forSquamous Cell Carcinoma of Head and Neck (SCCHN) Groupe Oncologie Radiotherapie Tete et Cou 131
Early research (Phase 1)UnknownNCT01149902What this trial is testingStudy of Chemo-Immunotherapy in Head and Neck Cancer PatientsWho this might be right forHead and Neck Cancer University of Yamanashi 10
Early research (Phase 1)Study completedNCT01976741What this trial is testingDose Escalation Pan-FGFR (Fibroblast Growth Factor Receptor) Inhibitor (Rogaratinib)Who this might be right forNeoplasms Bayer 168
Early research (Phase 1)Study completedNCT02013154What this trial is testingDKN-01 in Combination With Paclitaxel or PembrolizumabWho this might be right forEsophageal NeoplasmsAdenocarcinoma of the Gastroesophageal JunctionGastroesophageal Cancer+2 more Leap Therapeutics, Inc. 151
Testing effectiveness (Phase 2)Looking for participantsNCT05136196What this trial is testingBiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot StudyWho this might be right forClinical Stage III Cutaneous Melanoma AJCC v8Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8Clinical Stage IV Cutaneous Melanoma AJCC v8+22 more National Cancer Institute (NCI)
Not applicableStudy completedNCT02303444What this trial is testingAn Observational Study in Differentiated Thyroid Cancer Which is Radioactive Iodine (RAI) Refractory to Assess the Use of Multikinase InhibitorsWho this might be right forThyroid Neoplasms Bayer 667
Early research (Phase 1)Study completedNCT02574663What this trial is testingTGR-1202 Alone and in Combination With Either Nab-paclitaxel + Gemcitabine or With FOLFOX in Patients With Select Relapsed or Refractory Solid TumorsWho this might be right forPancreatic CancerColorectal CancerRectal Cancer+3 more TG Therapeutics, Inc. 66
Very early researchUnknownNCT05180851What this trial is testingSafety and Efficacy of Recombinant Oncolytic Adenovirus L-IFN Injection in Relapsed/Refractory Solid Tumors Clinical StudyWho this might be right forHead and Neck CancerMelanomaBreast Cancer+4 more Shanghai Fengxian District Central Hospital 28
Early research (Phase 1)Study completedNCT00003430What this trial is testingL-778,123 in Treating Patients With Recurrent or Refractory Solid TumorsWho this might be right forHead and Neck CancerUnspecified Adult Solid Tumor, Protocol Specific Memorial Sloan Kettering Cancer Center 40
Not applicableNo Longer AvailableNCT05225259What this trial is testingExpanded Access for LOXO-260 in Participants With Cancer Caused by an Abnormal RET Gene That Did Not Respond/is no Longer Responding to Treatment With a Type of Drug Called a RET InhibitorWho this might be right forCarcinoma, Non-Small-Cell LungThyroid Neoplasms Eli Lilly and Company
Testing effectiveness (Phase 2)Study completedNCT00381641What this trial is testingSunitinib Malate in Treating Patients With Thyroid Cancer That Did Not Respond to Iodine I 131 and Cannot Be Removed by SurgeryWho this might be right forDifferentiated Thyroid Gland CarcinomaRecurrent Thyroid Gland CarcinomaRefractory Thyroid Gland Carcinoma+16 more National Cancer Institute (NCI) 63
Testing effectiveness (Phase 2)Study completedNCT02689284What this trial is testingCombination Margetuximab and Pembrolizumab for Advanced, Metastatic HER2(+) Gastric or Gastroesophageal Junction CancerWho this might be right forGastric CancerStomach CancerEsophageal Cancer MacroGenics 95
Early research (Phase 1)Enrolling By InvitationNCT07218003What this trial is testingA Phase 1/1b of RNDO-564 Single Agent or in Combination With Pembrolizumab in Bladder Cancer and Other Solid Tumors Associated With Nectin-4Who this might be right forNon Small Cell Lung CancerCervical CancerHead and Neck Squamous Cell Cancer+7 more Rondo Therapeutics 149
Early research (Phase 1)Study completedNCT00020579What this trial is testingMS-275 in Treating Patients With Advanced Solid Tumors or LymphomaWho this might be right forCancer National Institutes of Health Clinical Center (CC) 75